Clinical Trial Update: Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating burosumab for FGF23-mediated hypophosphatemia in fibrous dysplasia has completed and posted its results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrous Dysplasia of Bone

Drugs mentioned

• Crysvita (burosumab)

Snippet

Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) | Conditions: Fibrous Dysplasia Of Bone | Phase 2 | Status: COMPLETED | Results posted: 2026-02-02